Simon Barry J.

Director Simon Barry J. sells 175,000 IBRX shares in 2 transactions for $1,783,601.50, reducing stake 5.6% while stock near 52-week high.

Simon Barry J., Director of ImmunityBio, executed two separate sales totaling 175,000 shares for $1,783,601.50 over three trading days at prices ranging from $9.25 to $10.25, with a blended average price of $10.19. This sale reduced his holdings from 3,100,821 shares to 2,925,821 shares, a reduction of 5.6%. The timing of these sales coincides with a period of significant price momentum: the stock has appreciated 79.1% over the prior 30 days and 442.2% over the prior 90 days, and now trades at $11.55, matching its 52-week high. His prior two sales at IBRX (both on 2026-01-20) had 30-day returns of +31.6% and +9.3%, indicating the stock continued rising after those transactions. The company operates with substantial losses ($-67,253,000 net income on quarterly revenue of $32,061,000), though it reported 668.3% annual revenue growth. The confluence of strong price appreciation, the director's decision to sell a material quantity of shares at prices below the current market level, and the company's unprofitable operational posture merit attention to whether this reflects conviction about valuation levels or execution against a pre-planned schedule.

Director Simon Barry J. sold 151,967 shares ($1.1M) in 2 transactions at ImmunityBio (IBRX) on 2026-01-20 as stock hits 52-week high of $6.92

Simon Barry J. executed 2 separate sales totaling 151,967 shares for $1,094,296.68 at a blended average price of $7.20, reducing his holdings from 3,243,571 shares to 3,091,604 shares (a 4.7% reduction). The timing coincides with the stock reaching its 52-week high of $6.92 and after substantial recent momentum: the stock has climbed 204.8% over the past 30 days and 189.5% over the past 90 days. Notably, this activity occurs in a company with significant cash burn—annual net income stands at negative $67,253,000—despite impressive top-line growth of 2270.6% year-over-year. The sale at elevated valuations relative to the 52-week trading range raises questions about asset allocation decisions at a point of peak momentum.